GCPII imaging and cancer

Research output: Contribution to journalArticle

Abstract

Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.

Original languageEnglish (US)
Pages (from-to)1346-1359
Number of pages14
JournalCurrent Medicinal Chemistry
Volume19
Issue number9
DOIs
StatePublished - Mar 2012

    Fingerprint

Keywords

  • molecular imaging
  • PET
  • prostate cancer
  • Prostate-specific membrane antigen
  • PSMA
  • SPECT

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this